The quartet of vaccine-makers from the western world are ascertaining the need to tweak their vaccines for the Omicron, whereas WHO states it is too early to comment on its virulence.
Syngene International was started by Biocon in 1993 to provide research services for pharma companies. Three decades later, the entity wants to become a global science company in its own right.
A great pharma and medical supply chain, large population, intent among health professionals to innovate, and willingness among customers to try new solutions will ensure the sector's success.
Three firms have applied for emergency use authorisation in India as of now. AIIMS’ Amit Dinda, who is a part of the Global Coalition for Regulatory Science Research, explains the regulatory nuances.
As the world awaits a panacea for Covid-19, pharma companies have their feet firmly on the accelerator to get people a safe vaccine to stem the spiral of death and illness looming over humanity.
